trending Market Intelligence /marketintelligence/en/news-insights/trending/wLotrLT8rpBc1h7c_eLByQ2 content esgSubNav
In This List

AFT Pharmaceuticals painkiller meets main goal in phase 3 trial

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


AFT Pharmaceuticals painkiller meets main goal in phase 3 trial

AFT Pharmaceuticals Ltd. said the phase 3 trial for the intravenous form of its Maxigesic painkiller met its main goal, showing that the drug provided superior pain relief compared to paracetamol, ibuprofen or placebo.

Results indicated a highly statistically significant difference between treatment groups in the primary endpoint for the improvement in sum of the pain intensity difference scores for Maxigesic in comparison with all other treatment groups.

The intravenous form of Maxigesic is a combination of 1000 milligrams of paracetamol plus 300mg of ibuprofen. It has been developed as a line extension to Maxigesic tablets primarily for postoperative usage in hospitals where patients cannot take oral medicine.

In May, the European Medicines Agency approved the Maxigesic painkiller for sale in nine additional EU member countries.